CytomX
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W.
CTMX Key Statistics
Stock Snapshot
With a market cap of 695.53M, CytomX(CTMX) trades at $4.10. The stock has a price-to-earnings ratio of 10.02.
As of 2025-11-12, CytomX(CTMX) stock has fluctuated between $4.02 and $4.24. The current price stands at $4.10, placing the stock +2.0% above today's low and -3.3% off the high.
The CytomX(CTMX)'s current trading volume is 2.54M, compared to an average daily volume of 4.7M.
In the last year, CytomX(CTMX) shares hit a 52-week high of $4.62 and a 52-week low of $0.40.
In the last year, CytomX(CTMX) shares hit a 52-week high of $4.62 and a 52-week low of $0.40.
CTMX News
Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $6.50 from $5 and keeps an Overweight rating on the shares. At SITC, CytomX presen...
Earnings Call Insights CytomX outlines Q1 2026 CX-2051 data update and 100-patient enrollment milestone as Phase Ib study nears Nov. 07, 2025 2:26 PM ET CytomX...
Reports Q3 revenue $5.96M, consensus $11.5M. “CytomX continued to execute against its pipeline priorities this quarter, highlighted by robust Phase 1 expansion...
Analyst ratings
88%
of 8 ratingsMore CTMX News
CytomX Therapeutics (CTMX) has drawn fresh attention after announcing plans to share initial translational and biomarker data for CX-801 at the Society for Immu...
